Medtronic cuts accused doctor loose

U.S. Sen. Charles Grassley expressed concern that a list of consultants provided to him by Medtronic doesn't include a doctor accused of falsifying data in a favorable study of the company's Infuse bone-graft product. Meanwhile, the device maker said Wednesday it had suspended its consulting agreement with the former military doctor accused by the Army of faking that research. Report | Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.